This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Nvidia petitions US patent board for review of three Neural AI patents

By Melissa Ritti ( February 26, 2025, 17:40 GMT | Insight) -- In concurrent filings earlier this week, Nvidia took aim at graphical processor unit technology utilized in advanced machine learning and other emerging tech it stands accused of infringing in Texas federal court. The California-based AI computing company asked the US Patent and Trademark Office’s Patent Trial and Appeal Board to cancel myriad claims of three Neural AI patents it says would have been obvious to a person of skill in the art, arguing that the use of an “accelerator controller” to perform advanced numerical simulations was not only already known, it was already patented by Nvidia, itself.Three Neural AI patents directed to improvements in graphical processor unit, or GPU, technologies were singled out earlier this week by Nvidia for inter partes review, or IPR, by the US Patent and Trademark Office’s Patent Trial and Appeal Board....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections